JP2007500721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500721A5 JP2007500721A5 JP2006522099A JP2006522099A JP2007500721A5 JP 2007500721 A5 JP2007500721 A5 JP 2007500721A5 JP 2006522099 A JP2006522099 A JP 2006522099A JP 2006522099 A JP2006522099 A JP 2006522099A JP 2007500721 A5 JP2007500721 A5 JP 2007500721A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antigen
- adenosine
- receptor
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 112
- 238000000034 method Methods 0.000 claims description 102
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 63
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 56
- 229960005305 adenosine Drugs 0.000 claims description 56
- 239000000427 antigen Substances 0.000 claims description 52
- 108091007433 antigens Proteins 0.000 claims description 52
- 102000036639 antigens Human genes 0.000 claims description 52
- 108020003175 receptors Proteins 0.000 claims description 49
- 102000005962 receptors Human genes 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 41
- 230000004044 response Effects 0.000 claims description 35
- 231100000433 cytotoxic Toxicity 0.000 claims description 29
- 230000001472 cytotoxic effect Effects 0.000 claims description 29
- 230000000890 antigenic effect Effects 0.000 claims description 19
- 210000003979 eosinophil Anatomy 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 239000012190 activator Substances 0.000 claims description 16
- 230000001965 increasing effect Effects 0.000 claims description 16
- 210000004443 dendritic cell Anatomy 0.000 claims description 13
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 12
- 210000001616 monocyte Anatomy 0.000 claims description 12
- 210000001865 kupffer cell Anatomy 0.000 claims description 11
- 210000004698 lymphocyte Anatomy 0.000 claims description 11
- 210000002540 macrophage Anatomy 0.000 claims description 11
- 210000000274 microglia Anatomy 0.000 claims description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 230000037452 priming Effects 0.000 claims description 10
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 9
- 239000002582 adenosine A1 receptor agonist Substances 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 230000007402 cytotoxic response Effects 0.000 claims description 9
- 238000000586 desensitisation Methods 0.000 claims description 9
- 210000002889 endothelial cell Anatomy 0.000 claims description 9
- 239000002158 endotoxin Substances 0.000 claims description 9
- 210000002950 fibroblast Anatomy 0.000 claims description 9
- 230000003281 allosteric effect Effects 0.000 claims description 8
- 239000003623 enhancer Substances 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 102000000589 Interleukin-1 Human genes 0.000 claims description 7
- 108010002352 Interleukin-1 Proteins 0.000 claims description 7
- 230000008512 biological response Effects 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000012636 effector Substances 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 230000003325 follicular Effects 0.000 claims description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 7
- 210000001821 langerhans cell Anatomy 0.000 claims description 7
- 210000005259 peripheral blood Anatomy 0.000 claims description 7
- 239000011886 peripheral blood Substances 0.000 claims description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 7
- 239000003909 protein kinase inhibitor Substances 0.000 claims description 7
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 claims description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 6
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 6
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 6
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 102100036845 C-C motif chemokine 22 Human genes 0.000 claims description 6
- 108010029697 CD40 Ligand Proteins 0.000 claims description 6
- 102100032937 CD40 ligand Human genes 0.000 claims description 6
- 108010083701 Chemokine CCL22 Proteins 0.000 claims description 6
- 102000006573 Chemokine CXCL12 Human genes 0.000 claims description 6
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 6
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 6
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 6
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 6
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 6
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 6
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 6
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 6
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 6
- 102000003815 Interleukin-11 Human genes 0.000 claims description 6
- 108090000177 Interleukin-11 Proteins 0.000 claims description 6
- 102000013462 Interleukin-12 Human genes 0.000 claims description 6
- 108010065805 Interleukin-12 Proteins 0.000 claims description 6
- 102000003812 Interleukin-15 Human genes 0.000 claims description 6
- 108090000172 Interleukin-15 Proteins 0.000 claims description 6
- 102000013691 Interleukin-17 Human genes 0.000 claims description 6
- 108050003558 Interleukin-17 Proteins 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 108010002386 Interleukin-3 Proteins 0.000 claims description 6
- 102000004388 Interleukin-4 Human genes 0.000 claims description 6
- 108090000978 Interleukin-4 Proteins 0.000 claims description 6
- 102000004889 Interleukin-6 Human genes 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 102100021592 Interleukin-7 Human genes 0.000 claims description 6
- 108010002586 Interleukin-7 Proteins 0.000 claims description 6
- 102000004890 Interleukin-8 Human genes 0.000 claims description 6
- 108090001007 Interleukin-8 Proteins 0.000 claims description 6
- 102000000585 Interleukin-9 Human genes 0.000 claims description 6
- 108010002335 Interleukin-9 Proteins 0.000 claims description 6
- 108010003541 Platelet Activating Factor Proteins 0.000 claims description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 6
- 102100038358 Prostate-specific antigen Human genes 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 231100000655 enterotoxin Toxicity 0.000 claims description 6
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229940074383 interleukin-11 Drugs 0.000 claims description 6
- 229940117681 interleukin-12 Drugs 0.000 claims description 6
- 229940076264 interleukin-3 Drugs 0.000 claims description 6
- 229940028885 interleukin-4 Drugs 0.000 claims description 6
- 229940100601 interleukin-6 Drugs 0.000 claims description 6
- 229940100994 interleukin-7 Drugs 0.000 claims description 6
- 229940096397 interleukin-8 Drugs 0.000 claims description 6
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 6
- 229940118526 interleukin-9 Drugs 0.000 claims description 6
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 6
- 230000005012 migration Effects 0.000 claims description 6
- 238000013508 migration Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 210000004988 splenocyte Anatomy 0.000 claims description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 108700012359 toxins Proteins 0.000 claims description 6
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 5
- 102000003816 Interleukin-13 Human genes 0.000 claims description 5
- 108090000176 Interleukin-13 Proteins 0.000 claims description 5
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 5
- 229960000623 carbamazepine Drugs 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- 229960000975 daunorubicin Drugs 0.000 claims description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 5
- 239000003975 dentin desensitizing agent Substances 0.000 claims description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
- 229960003957 dexamethasone Drugs 0.000 claims description 5
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- 210000003714 granulocyte Anatomy 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000004232 Enteritis Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 102000003814 Interleukin-10 Human genes 0.000 claims description 4
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 102000049772 Interleukin-16 Human genes 0.000 claims description 4
- 101800003050 Interleukin-16 Proteins 0.000 claims description 4
- 102100039897 Interleukin-5 Human genes 0.000 claims description 4
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 206010057249 Phagocytosis Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 239000002269 analeptic agent Substances 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 4
- 230000009089 cytolysis Effects 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 238000004520 electroporation Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 229940076144 interleukin-10 Drugs 0.000 claims description 4
- 229940100602 interleukin-5 Drugs 0.000 claims description 4
- 229940043355 kinase inhibitor Drugs 0.000 claims description 4
- 229960001156 mitoxantrone Drugs 0.000 claims description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 230000008782 phagocytosis Effects 0.000 claims description 4
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 201000009032 substance abuse Diseases 0.000 claims description 4
- 231100000736 substance abuse Toxicity 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 3
- 108010060263 Adenosine A1 Receptor Proteins 0.000 claims description 3
- 102000030814 Adenosine A1 receptor Human genes 0.000 claims description 3
- 244000036975 Ambrosia artemisiifolia Species 0.000 claims description 3
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 claims description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 3
- 102100022987 Angiogenin Human genes 0.000 claims description 3
- 102400000068 Angiostatin Human genes 0.000 claims description 3
- 108010079709 Angiostatins Proteins 0.000 claims description 3
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims description 3
- 108091008875 B cell receptors Proteins 0.000 claims description 3
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 3
- 102100023703 C-C motif chemokine 15 Human genes 0.000 claims description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 3
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 3
- 108700012434 CCL3 Proteins 0.000 claims description 3
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 3
- 102000000013 Chemokine CCL3 Human genes 0.000 claims description 3
- 108010055165 Chemokine CCL4 Proteins 0.000 claims description 3
- 102000001326 Chemokine CCL4 Human genes 0.000 claims description 3
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 108010078546 Complement C5a Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 3
- 102400001047 Endostatin Human genes 0.000 claims description 3
- 108010079505 Endostatins Proteins 0.000 claims description 3
- 101710146739 Enterotoxin Proteins 0.000 claims description 3
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 3
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 3
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 108010000916 Fimbriae Proteins Proteins 0.000 claims description 3
- 108010040721 Flagellin Proteins 0.000 claims description 3
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- 229930186217 Glycolipid Natural products 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 108700010013 HMGB1 Proteins 0.000 claims description 3
- 101150021904 HMGB1 gene Proteins 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 102100037907 High mobility group protein B1 Human genes 0.000 claims description 3
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 3
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 claims description 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 3
- 101000654734 Homo sapiens Septin-4 Proteins 0.000 claims description 3
- 102000002227 Interferon Type I Human genes 0.000 claims description 3
- 108010014726 Interferon Type I Proteins 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 3
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 3
- 102100037611 Lysophospholipase Human genes 0.000 claims description 3
- 102000034655 MIF Human genes 0.000 claims description 3
- 108060004872 MIF Proteins 0.000 claims description 3
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 3
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims description 3
- 102100034256 Mucin-1 Human genes 0.000 claims description 3
- 108010063954 Mucins Proteins 0.000 claims description 3
- 102000015728 Mucins Human genes 0.000 claims description 3
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- 208000030852 Parasitic disease Diseases 0.000 claims description 3
- 108010013639 Peptidoglycan Proteins 0.000 claims description 3
- 108010058864 Phospholipases A2 Proteins 0.000 claims description 3
- 102000029797 Prion Human genes 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 102000005569 Protein Phosphatase 1 Human genes 0.000 claims description 3
- 108010059000 Protein Phosphatase 1 Proteins 0.000 claims description 3
- 102000006478 Protein Phosphatase 2 Human genes 0.000 claims description 3
- 108010058956 Protein Phosphatase 2 Proteins 0.000 claims description 3
- 102000016611 Proteoglycans Human genes 0.000 claims description 3
- 108010067787 Proteoglycans Proteins 0.000 claims description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 3
- 108010080192 Purinergic Receptors Proteins 0.000 claims description 3
- 102000000033 Purinergic Receptors Human genes 0.000 claims description 3
- 108091008874 T cell receptors Proteins 0.000 claims description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 3
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims description 3
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 3
- 101710097161 Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 claims description 3
- 102100039094 Tyrosinase Human genes 0.000 claims description 3
- 108060008724 Tyrosinase Proteins 0.000 claims description 3
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 229920000392 Zymosan Polymers 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000000961 alloantigen Effects 0.000 claims description 3
- 108010072788 angiogenin Proteins 0.000 claims description 3
- 235000003484 annual ragweed Nutrition 0.000 claims description 3
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 claims description 3
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims description 3
- 235000006263 bur ragweed Nutrition 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 239000013592 cell lysate Substances 0.000 claims description 3
- 235000003488 common ragweed Nutrition 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 239000000147 enterotoxin Substances 0.000 claims description 3
- 229940116977 epidermal growth factor Drugs 0.000 claims description 3
- 231100000776 exotoxin Toxicity 0.000 claims description 3
- 239000002095 exotoxin Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 3
- 150000002617 leukotrienes Chemical class 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 238000012737 microarray-based gene expression Methods 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 229940051875 mucins Drugs 0.000 claims description 3
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 3
- 230000001338 necrotic effect Effects 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 239000002777 nucleoside Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 150000003180 prostaglandins Chemical class 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 208000028172 protozoa infectious disease Diseases 0.000 claims description 3
- 235000009736 ragweed Nutrition 0.000 claims description 3
- 230000009257 reactivity Effects 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 231100000617 superantigen Toxicity 0.000 claims description 3
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 230000033289 adaptive immune response Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 2
- 239000008365 aqueous carrier Substances 0.000 claims description 2
- 210000003651 basophil Anatomy 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 230000015788 innate immune response Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 claims description 2
- 210000004180 plasmocyte Anatomy 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000003614 tolerogenic effect Effects 0.000 claims description 2
- 230000002476 tumorcidal effect Effects 0.000 claims description 2
- 102100039064 Interleukin-3 Human genes 0.000 claims 4
- 108091006084 receptor activators Proteins 0.000 claims 4
- 102000055025 Adenosine deaminases Human genes 0.000 claims 2
- 102100027211 Albumin Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 2
- 229920001503 Glucan Polymers 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 210000001541 thymus gland Anatomy 0.000 claims 2
- 108091014434 Neurabin-2 Proteins 0.000 claims 1
- 102100034437 Neurabin-2 Human genes 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000000367 immunologic factor Substances 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- -1 MIP-3α Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49151003P | 2003-07-31 | 2003-07-31 | |
| PCT/US2004/024693 WO2005026318A2 (en) | 2003-07-31 | 2004-07-30 | Methods and compositions for producing antigenic responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007500721A JP2007500721A (ja) | 2007-01-18 |
| JP2007500721A5 true JP2007500721A5 (https=) | 2007-09-13 |
Family
ID=34312159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522099A Pending JP2007500721A (ja) | 2003-07-31 | 2004-07-30 | 抗原応答を生じさせる方法及び組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8247231B2 (https=) |
| EP (1) | EP1651259A4 (https=) |
| JP (1) | JP2007500721A (https=) |
| CA (1) | CA2533926C (https=) |
| WO (1) | WO2005026318A2 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2876798A1 (fr) * | 2004-10-14 | 2006-04-21 | Univ Clermont Auvergne | Diagnostic et traitement de la maladie de crohn |
| PT2347775T (pt) | 2005-12-13 | 2020-07-14 | The President And Fellows Of Harvard College | Estruturas em andaime para transplante celular |
| US9770535B2 (en) | 2007-06-21 | 2017-09-26 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
| US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
| US10328133B2 (en) | 2008-02-13 | 2019-06-25 | President And Fellows Of Harvard College | Continuous cell programming devices |
| ES2621406T3 (es) | 2008-05-19 | 2017-07-04 | Dcprime B.V. | Método de inducción y de aceleración de células |
| US9012399B2 (en) | 2008-05-30 | 2015-04-21 | President And Fellows Of Harvard College | Controlled release of growth factors and signaling molecules for promoting angiogenesis |
| WO2010120749A2 (en) | 2009-04-13 | 2010-10-21 | President And Fellow Of Harvard College | Harnessing cell dynamics to engineer materials |
| EP2461828B1 (en) * | 2009-07-31 | 2017-06-21 | President and Fellows of Harvard College | Programming of cells for tolerogenic therapies |
| WO2011109834A2 (en) | 2010-03-05 | 2011-09-09 | President And Fellows Of Harvard College | Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1 |
| EP2555627A4 (en) * | 2010-04-06 | 2013-10-23 | John W Holaday | METHOD FOR TREATING CARCINOMA |
| EP2585053A4 (en) | 2010-06-25 | 2014-02-26 | Harvard College | COMMON RELEASE OF STIMULATING AND HEMMING FACTORS FOR THE PRODUCTION OF TEMPORARY STABILIZED AND SPATULARLY LIMITED ZONES |
| WO2012037361A2 (en) * | 2010-09-15 | 2012-03-22 | Endacea, Inc. | Methods of use and kit for measurement of lipopolysaccharide with a time resolved fluorescence based assay |
| JP6104806B2 (ja) | 2010-10-06 | 2017-03-29 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル |
| US9603894B2 (en) | 2010-11-08 | 2017-03-28 | President And Fellows Of Harvard College | Materials presenting notch signaling molecules to control cell behavior |
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| WO2012148684A1 (en) | 2011-04-27 | 2012-11-01 | President And Fellows Of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
| US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
| EP2701745B1 (en) | 2011-04-28 | 2018-07-11 | President and Fellows of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
| WO2012167230A1 (en) | 2011-06-03 | 2012-12-06 | President And Fellows Of Harvard College | In situ antigen-generating cancer vaccine |
| CN104244929B (zh) | 2012-04-16 | 2017-04-05 | 哈佛学院董事会 | 用于调节免疫反应的介孔二氧化硅组合物 |
| JP6283347B2 (ja) * | 2013-03-06 | 2018-02-21 | タカラバイオ株式会社 | 成熟樹状細胞集団の製造方法 |
| JP7348708B2 (ja) | 2014-04-30 | 2023-09-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 組み合わせワクチン装置および癌細胞を殺滅する方法 |
| HK1247861A1 (zh) | 2015-01-30 | 2018-10-05 | President And Fellows Of Harvard College | 用於癌症治疗的肿瘤周围和肿瘤内部材料 |
| WO2016164705A1 (en) | 2015-04-10 | 2016-10-13 | Omar Abdel-Rahman Ali | Immune cell trapping devices and methods for making and using the same |
| CN104830799A (zh) * | 2015-05-05 | 2015-08-12 | 杨光华 | 基于psa抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途 |
| EP3325610B1 (en) * | 2015-07-17 | 2020-03-25 | Ares Trading S.A. | Methods for modulating production profiles of recombinant proteins |
| EP3411475B1 (en) | 2016-02-06 | 2025-08-27 | President and Fellows of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
| CN115404196A (zh) | 2016-07-13 | 2022-11-29 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
| CN110418651A (zh) | 2016-08-02 | 2019-11-05 | 哈佛学院院长等 | 用于调节免疫应答的生物材料 |
| WO2019183924A1 (en) * | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
| WO2020061129A1 (en) | 2018-09-19 | 2020-03-26 | President And Fellows Of Harvard College | Compositions and methods for labeling and modulation of cells in vitro and in vivo |
| WO2020201828A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| CN112175906B (zh) * | 2019-07-05 | 2023-09-29 | 中国科学院生物物理研究所 | 胸腺嘧啶核苷诱导成纤维细胞转分化在中性粒细胞减少症治疗中的应用 |
| EP4017534A4 (en) * | 2019-08-19 | 2023-12-27 | Wayne State University | IN VIVO IMMUNOIMAGING OF INTERLEUKIN-12 |
| WO2021061837A1 (en) | 2019-09-23 | 2021-04-01 | President And Fellows Of Harvard College | Biomaterial-based antigen free vaccine and the use thereof |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| AU2022211682A1 (en) | 2021-01-22 | 2023-08-03 | Mendus B.V. | Methods of tumor vaccination |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3920811A (en) * | 1972-12-22 | 1975-11-18 | Cutter Lab | Adjuvant compositions |
| US6159701A (en) * | 1996-11-08 | 2000-12-12 | Link Technology Incorporated | Method and compositions for treating and diagnosing tumors using adenosine receptor activated cells |
| US20020160415A1 (en) * | 1999-05-14 | 2002-10-31 | Neely Constance F. | Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for the prevention of cancer in at- risk subjects |
| US6680052B1 (en) * | 1999-11-08 | 2004-01-20 | Endacea, Inc. | Methods of inhibiting tumor growth using adenosine receptor activated cells |
| WO2002095391A1 (en) | 2001-05-24 | 2002-11-28 | Endacea Inc. | Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor |
| EP1465634B1 (en) * | 2001-12-12 | 2014-10-22 | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services | Methods for using adenosine receptor inhibitors to enhance immune response and inflammation |
-
2004
- 2004-07-30 WO PCT/US2004/024693 patent/WO2005026318A2/en not_active Ceased
- 2004-07-30 US US10/903,933 patent/US8247231B2/en not_active Expired - Fee Related
- 2004-07-30 CA CA2533926A patent/CA2533926C/en not_active Expired - Fee Related
- 2004-07-30 EP EP04816171A patent/EP1651259A4/en not_active Withdrawn
- 2004-07-30 JP JP2006522099A patent/JP2007500721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500721A5 (https=) | ||
| CA2533926C (en) | Methods and compositions for producing antigenic responses | |
| Sakuishi et al. | Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation | |
| Groot Kormelink et al. | The role of extracellular vesicles when innate meets adaptive | |
| Ronchi et al. | Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1β production by myeloid cells | |
| Krishnamoorthy et al. | Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma | |
| Rosenberg et al. | Eosinophils: changing perspectives in health and disease | |
| Kunkel et al. | The role of chemokines in inflammatory joint disease | |
| Klaas et al. | Sialoadhesin promotes rapid proinflammatory and type I IFN responses to a sialylated pathogen, Campylobacter jejuni | |
| Baumgart et al. | Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis | |
| Jen et al. | Increased serum interleukin‐17 and peripheral Th17 cells in children with acute Henoch–Schönlein purpura | |
| US20230265150A1 (en) | A fusion proteon of stromal cell-derived factor-1 (sdf-1) and interleukin-2 (il-2) and applications thereof | |
| RU2578420C2 (ru) | Иммуностимулирующие и вакцинные композиции | |
| Regamey et al. | Airway epithelial IL-15 transforms monocytes into dendritic cells | |
| Rahman et al. | Mucosal-associated invariant T (MAIT) cells provide B-cell help in vaccinated and subsequently SIV-infected Rhesus Macaques | |
| JP2010534200A5 (https=) | ||
| Samitas et al. | B cells: from early development to regulating allergic diseases | |
| Caprioli et al. | Th17 immune response in IBD: A new pathogenic mechanism | |
| Oppenheim et al. | Chemokine receptors on dendritic cells promote autoimmune reactions | |
| Katakai et al. | Th1-biased tertiary lymphoid tissue supported by CXC chemokine ligand 13-producing stromal network in chronic lesions of autoimmune gastritis | |
| Le et al. | Desensitization of chemokine receptor CCR5 in dendritic cells at the early stage of differentiation by activation of formyl peptide receptors | |
| Corvino et al. | Serum interleukin-18 and soluble tumour necrosis factor receptor 2 are associated with disease severity in patients with paracoccidioidomycosis | |
| Kikuchi et al. | Involvement of fractalkine/CX3CL1 expression by dendritic cells in the enhancement of host immunity against Legionella pneumophila | |
| US20250049911A1 (en) | Implantable scaffolds for immunotherapeutic and other uses | |
| CA2309602A1 (en) | Methods and compositions for enhancing immune response and for the production of in vitro mabs |